Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy
Despite all the other cells that have the potential to prevent cancer development and metastasis through tumour suppressor proteins, cancer cells can upregulate the ubiquitin–proteasome system (UPS) by which they can degrade tumour suppressor proteins and avoid apoptosis. This system plays an extens...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Royal Society
2021-04-01
|
| Series: | Open Biology |
| Subjects: | |
| Online Access: | https://royalsocietypublishing.org/doi/10.1098/rsob.200390 |
| _version_ | 1797985276370354176 |
|---|---|
| author | Fatemeh Aliabadi Beheshteh Sohrabi Ebrahim Mostafavi Hamidreza Pazoki-Toroudi Thomas J. Webster |
| author_facet | Fatemeh Aliabadi Beheshteh Sohrabi Ebrahim Mostafavi Hamidreza Pazoki-Toroudi Thomas J. Webster |
| author_sort | Fatemeh Aliabadi |
| collection | DOAJ |
| description | Despite all the other cells that have the potential to prevent cancer development and metastasis through tumour suppressor proteins, cancer cells can upregulate the ubiquitin–proteasome system (UPS) by which they can degrade tumour suppressor proteins and avoid apoptosis. This system plays an extensive role in cell regulation organized in two steps. Each step has an important role in controlling cancer. This demonstrates the importance of understanding UPS inhibitors and improving these inhibitors to foster a new hope in cancer therapy. UPS inhibitors, as less invasive chemotherapy drugs, are increasingly used to alleviate symptoms of various cancers in malignant states. Despite their success in reducing the development of cancer with the lowest side effects, thus far, an appropriate inhibitor that can effectively inactivate this system with the least drug resistance has not yet been fully investigated. A fundamental understanding of the system is necessary to fully elucidate its role in causing/controlling cancer. In this review, we first comprehensively investigate this system, and then each step containing ubiquitination and protein degradation as well as their inhibitors are discussed. Ultimately, its advantages and disadvantages and some perspectives for improving the efficiency of these inhibitors are discussed. |
| first_indexed | 2024-04-11T07:15:29Z |
| format | Article |
| id | doaj.art-5e29f630c53f46aab095d10e8352d882 |
| institution | Directory Open Access Journal |
| issn | 2046-2441 |
| language | English |
| last_indexed | 2024-04-11T07:15:29Z |
| publishDate | 2021-04-01 |
| publisher | The Royal Society |
| record_format | Article |
| series | Open Biology |
| spelling | doaj.art-5e29f630c53f46aab095d10e8352d8822022-12-22T04:38:01ZengThe Royal SocietyOpen Biology2046-24412021-04-0111410.1098/rsob.200390Ubiquitin–proteasome system and the role of its inhibitors in cancer therapyFatemeh Aliabadi0Beheshteh Sohrabi1Ebrahim Mostafavi2Hamidreza Pazoki-Toroudi3Thomas J. Webster4Physiology Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, IranDepartment of Chemistry, Surface Chemistry Research Laboratory, Iran University of Science and Technology, PO Box 16846-13114, Tehran, IranDepartment of Chemical Engineering, Northeastern University, Boston, MA 02115, USAPhysiology Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, IranDepartment of Chemical Engineering, Northeastern University, Boston, MA 02115, USADespite all the other cells that have the potential to prevent cancer development and metastasis through tumour suppressor proteins, cancer cells can upregulate the ubiquitin–proteasome system (UPS) by which they can degrade tumour suppressor proteins and avoid apoptosis. This system plays an extensive role in cell regulation organized in two steps. Each step has an important role in controlling cancer. This demonstrates the importance of understanding UPS inhibitors and improving these inhibitors to foster a new hope in cancer therapy. UPS inhibitors, as less invasive chemotherapy drugs, are increasingly used to alleviate symptoms of various cancers in malignant states. Despite their success in reducing the development of cancer with the lowest side effects, thus far, an appropriate inhibitor that can effectively inactivate this system with the least drug resistance has not yet been fully investigated. A fundamental understanding of the system is necessary to fully elucidate its role in causing/controlling cancer. In this review, we first comprehensively investigate this system, and then each step containing ubiquitination and protein degradation as well as their inhibitors are discussed. Ultimately, its advantages and disadvantages and some perspectives for improving the efficiency of these inhibitors are discussed.https://royalsocietypublishing.org/doi/10.1098/rsob.200390cancertargeted therapyubiquitin–proteasome systemubiquitination inhibitorsprotein degradation inhibitors |
| spellingShingle | Fatemeh Aliabadi Beheshteh Sohrabi Ebrahim Mostafavi Hamidreza Pazoki-Toroudi Thomas J. Webster Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy Open Biology cancer targeted therapy ubiquitin–proteasome system ubiquitination inhibitors protein degradation inhibitors |
| title | Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy |
| title_full | Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy |
| title_fullStr | Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy |
| title_full_unstemmed | Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy |
| title_short | Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy |
| title_sort | ubiquitin proteasome system and the role of its inhibitors in cancer therapy |
| topic | cancer targeted therapy ubiquitin–proteasome system ubiquitination inhibitors protein degradation inhibitors |
| url | https://royalsocietypublishing.org/doi/10.1098/rsob.200390 |
| work_keys_str_mv | AT fatemehaliabadi ubiquitinproteasomesystemandtheroleofitsinhibitorsincancertherapy AT beheshtehsohrabi ubiquitinproteasomesystemandtheroleofitsinhibitorsincancertherapy AT ebrahimmostafavi ubiquitinproteasomesystemandtheroleofitsinhibitorsincancertherapy AT hamidrezapazokitoroudi ubiquitinproteasomesystemandtheroleofitsinhibitorsincancertherapy AT thomasjwebster ubiquitinproteasomesystemandtheroleofitsinhibitorsincancertherapy |